Submissions received by the Committee

The Government's administration of the Pharmaceutical Benefits Scheme (PBS)

Submissions received by the Committee

Sub No.

1	Private Mental Health Consumer Carer Network (Australia) (PDF 612KB)
2	Mrs Geraldine Robertson (PDF 22KB)
3	Mr Brian Stafford (PDF 13KB)
4	Chronic Illness Alliance (PDF 82KB)
5	Diabetes Australia (PDF 69KB)
6	National Association of People Living with HIV/AIDS (NAPWA) (PDF 140KB)
7	Council of Social Service Network (PDF 197KB)
8	Cancer Voices Australia (PDF 238KB)
9	Consumers Health Forum of Australia (CHF) (PDF 288KB) Attachment 1(PDF 784KB) Attachment 2(PDF 500KB) Attachment 3(PDF 146KB)
10	SANE Australia (PDF 276KB)
11	iNova Pharmaceuticals (Aust) Pty Ltd (PDF 184KB)
12	Research Australia (PDF 252KB)
13	Mental Illness Fellowship of Australia (PDF 558KB)
14	Australian Pain Management Association Inc. (APMA) (PDF 608KB)
15	Painaustralia Limited (PDF 125KB)
16	Australian Medical Association (PDF 117KB)
17	Brain Tumour Alliance Australia Incorporated (BTAA) (PDF 139KB)
18	Cystic Fibrosis Australia (PDF 84KB)
19	Deakin Health Economics, Deakin University (PDF 348KB)
20	The Australian Lung Foundation (PDF 67KB)
21	Hepatitis Australia (PDF 108KB)
22	Osteoporosis Australia (PDF 49KB)
23	Novo Nordisk (PDF 262KB)
24	Breast Cancer Network Australia (BCNA) (PDF 263KB)
25	Arthritis Australia (PDF 186KB)
26	Positive Life NSW (PDF 173KB)
27	Australasian College of Dermatologists (PDF 214KB)
28	ACON (PDF 381KB)
29	Sanofi (PDF 98KB)
30	Queensland Positive People (QPP) (PDF 163KB)
31	Generic Medicines Industry Association (GMiA) (PDF 664KB)
32	Joint submission from Cancer Council Australia, the Clinical Oncological Society of Australia and the Medical Oncology Group of Australia (PDF 60KB)
33	Health Consumers' Council (WA) (PDF 17KB)
34	Medical Oncology Group of Australia (MOGA) (PDF 75KB)
35	Pfizer Australia (PDF 738KB)
36	Medicines Australia (PDF 900KB)
37	Janssen-Cilag Pty Ltd (PDF 918KB)
38	Mundipharma Pty Ltd (PDF 346KB)
39	Roche (PDF 509KB)
40	Arafmi Mental Health Carers and Friends Association (WA) Inc (PDF 78KB)
41	Australian Federation of AIDS Organisations (AFAO) (PDF 105KB)
42	Amgen Australia Pty Ltd (PDF 199KB)
43	MS Australia (PDF 182KB)
44	GlaxoSmithKline Australia (PDF 112KB)
45	Allergan Australia Pty Ltd (PDF 555KB)
46	The Department of Health and Ageing (DoHA) (PDF 173KB)
47	AstraZeneca Australia Pty Ltd (PDF 250KB)
48	Ms Elizabeth Trapani (PDF 50KB) Attachment 1(PDF 230KB) Attachment 2(PDF 103KB)
49	Cancer Voices NSW (PDF 103KB)
50	National Seniors Australia (PDF 64KB)
51	Ms Janne Graham (PDF 79KB)
52	Ms Carol Hughes (PDF 68KB)
53	Mental Health Council of Australia (PDF 239KB)
54	Ms Elizabeth Graham (PDF 42KB)
55	Name Withheld (PDF 32KB)
56	Australian Pompe's Association (PDF 339KB)
57	Professor Matthew Peters (PDF 29KB)
58	Ms Valerie Hanrahan (PDF 19KB)
59	Health Consumers NSW (PDF 266KB)
60	Fabry Support Group Australia (FGSA) (PDF 347KB)
61	The Royal Australasian College of Physicians (RACP) (PDF 37KB)
62	Northern Territory Government Department of Health (PDF 31KB)
63	Department of Health - Western Australia (PDF 398KB)
64	Confidential
65	Dr Kathryn Antioch (PDF 84KB) Attachment 1(PDF 80KB)

Additional Information Received

1	Generic Medicines Industry Association (GMiA), Case study â€“ amiloride, tabled at the Melbourne public hearing on 21 July 2011(PDF 77KB)
2	Chronic Illness Alliance, 'Prescription drug subsidies in Australia and New Zealand', Australian Prescriber, Vol 33, No. 1, February 2010, tabled at the Melbourne public hearing on 21 July 2011(PDF 880KB)
3	Allergan Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011, provided on 29 July 2011(PDF 86KB)
4	Mundipharma Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 5 August 2011 2011, provided on 5 August 2011(PDF 195KB)
5	Janssen-Cilag Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 5 August 2011(PDF 192KB)
6	Medicines Australia, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 8 August 2011(PDF 188KB)
7	Pharmaceutical Benefits Advisory Committee, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 9 August 2011(PDF 108KB)
8	Pfizer Australia, Answers to Questions on Notice taken at the Melbourne public hearing on 21 July 2011 and additional information, provided on 10 August 2011(PDF 695KB)
9	Department of Health and Ageing, Answers to Questions on Notice taken at the Canberra public hearing on 25 July 2011, provided on 12 August 2011(PDF 75KB)

For further information, contact:

Senate Finance and Public Administration Committees
PO Box 6100
Parliament House
Canberra ACT 2600
Australia
Phone: +61 2 6277 3439
Fax: +61 2 6277 5809
Email: fpa.sen@aph.gov.au

Phone:	+61 2 6277 3439
Fax:	+61 2 6277 5809
Email:	fpa.sen@aph.gov.au